Abstract:ABSTRACT The four serotypes of dengue virus (DENV-1 to -4) represent the most prevalent mosquito-borne viral pathogens in humans. No clinically approved vaccine or antiviral is currently available for DENV. Here we report a spiropyrazolopyridone compound that potently inhibits DENV both in vitro and in vivo. The inhibitor was identified through screening of a 1.8-million-compound library by using a DENV-2 replicon assay. The compound selectively inhibits DENV-2 and -3 (50% effective concentration [EC50], 10 to 80 nM) but not DENV-1 and -4 (EC50, >20 μM). Resistance analysis showed that a mutation at amino acid 63 of DENV-2 NS4B (a nonenzymatic transmembrane protein and a component of the viral replication complex) could confer resistance to compound inhibition. Genetic studies demonstrate that variations at amino acid 63 of viral NS4B are responsible for the selective inhibition of DENV-2 and -3. Medicinal chemistry improved the physicochemical properties of the initial “hit” (compound 1), leading to compound 14a, which has good in vivo pharmacokinetics. Treatment of DENV-2-infected AG129 mice with compound 14a suppressed viremia, even when the treatment started after viral infection. The results have proven the concept that inhibitors of NS4B could potentially be developed for clinical treatment of DENV infection. Compound 14a represents a potential preclinical candidate for treatment of DENV-2- and -3-infected patients. IMPORTANCE Dengue virus (DENV) threatens up to 2.5 billion people and is now spreading in many regions in the world where it was not previously endemic. While there are several promising vaccine candidates in clinical trials, approved vaccines or antivirals are not yet available. Here we describe the identification and characterization of a spiropyrazolopyridone as a novel inhibitor of DENV by targeting the viral NS4B protein. The compound potently inhibits two of the four serotypes of DENV (DENV-2 and -3) both in vitro and in vivo. Our results validate, for the first time, that NS4B inhibitors could potentially be developed for antiviral therapy for treatment of DENV infection in humans.

All-Atom Perspective of the DENV-3 Methyltransferase Inhibition Mechanism

Small Molecule Inhibitors That Selectively Block Dengue Virus Methyltransferase

Investigation of natural compounds as methyltransferase inhibitors against dengue virus: an in silico approach

Mechanistic insights into the inhibition of dengue virus NS5 methyltransferase by herbacetin

Identification of a Pyridoxine-Derived Small-Molecule Inhibitor Targeting Dengue Virus RNA-Dependent RNA Polymerase

SAM-dependent viral MTase inhibitors: herbacetin and caffeic acid phenethyl ester, structural insights into dengue MTase

LncRNA-SNHG1 contributes to gastric cancer cell proliferation by regulating DNMT1.

Inhibition of Dengue Virus Polymerase by Blocking of the RNA Tunnel.

Analysis of the nucleoside triphosphatase, RNA triphosphatase, and unwinding activities of the helicase domain of dengue virus NS3 protein

Myricetin Allosterically Inhibits the Dengue NS2B-NS3 Protease by Disrupting the Active and Locking the Inactive Conformations

Design, synthesis and biological activity evaluation of novel allosteric inhibitors of the DENV NS2B–NS3 protease

Molecular Characterization and Identification of Potential Inhibitors for 'E' Protein of Dengue Virus

Computational design and in vitro assay of lantadene-based novel inhibitors of NS3 protease of dengue virus

Allostery in the dengue virus NS3 helicase: Insights into the NTPase cycle from molecular simulations

N-Phenylpyridine-3-Carboxamide and 6-Acetyl-1H-Indazole Inhibit the RNA Replication Step of the Dengue Virus Life Cycle

Identification of an Arylnaphthalene Lignan Derivative as an Inhibitor against Dengue Virus Serotypes 1 to 4 (DENV-1 to -4) Using a Newly Developed DENV-3 Infectious Clone and Replicon

Inhibition of dengue viruses by N-methylcytisine thio derivatives through targeting viral envelope protein and NS2B-NS3 protease

Discovery of Dengue Virus Ns4b Inhibitors

Discovery of highly potent DENV NS2B-NS3 covalent inhibitors containing a phenoxymethylphenyl residue

Characterization Of A Candidate Tetravalent Vaccine Based On 2 '-O-Methyltransferase Mutants

An Adenosine Nucleoside Inhibitor of Dengue Virus.